GlassScriptPhysician profile
Edward P Perez
NPI 1881755650
$4,288.23
in general payments reported to CMS, 2019-2025
24 companies · $568 in 2025
The $568 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,166 · 2020: $93.96 · 2021: $156 · 2022: $578 · 2023: $280 · 2024: $447 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.39 |
| Education | $185.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $650.46 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $526.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $485.00 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $330.18 | 2019 | |
| Janssen Scientific Affairs, LLC | $272.15 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $232.88 | 2019-2025 | |
| Leo Pharma INC. | $214.92 | 2019-2025 | Adbry |
| Incyte Corporation | $170.37 | 2021-2025 | Opzelura |
| Ucb, INC. | $168.40 | 2023-2025 | Bimzelx |
| Biofrontera INC. | $151.37 | 2019 | |
| Galderma Laboratories, L.P. | $148.98 | 2019 | |
| Amgen INC. | $143.95 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $128.19 | 2019-2022 | |
| Lilly USA, LLC | $116.69 | 2019-2023 | Taltz, Olumiant |
| Celgene Corporation | $113.53 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $102.66 | 2022-2025 | Sotyktu |
| Pfizer INC. | $76.05 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $62.91 | 2019-2024 | Libtayo |
| Zimmer Biomet Holdings, INC. | $61.39 | 2022 | |
| Allergan, INC. | $47.71 | 2019 | |
| Dusa Pharmaceuticals, INC. | $32.72 | 2019 | |
| Genentech USA, INC. | $21.68 | 2022 | |
| Dermira, INC. | $18.12 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.